盐酸安罗替尼治疗晚期非小细胞肺癌患者的临床疗效

doi:10.3969/j.issn.1006-6233.2020.10.037

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1190 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To observe the quality of life and clinical efficacy on anlotinib hydrochloride in the treatment of advanced non-small cell lung cancer patients. Methods: 37 cases who were diagnosed with non-small cell lung cancer were collected from our hospital;anlotinib hydrochloride was administered to all patients, once a day, 12 mg a time, before breakfast, then the clinical efficacy, effect on patients' quality of life, and adverse reactions of anlotinib hydrochloride in the treatment of this disease were analyzed. Results: The objective remission rate was 35.1%, while the disease control rate of anlotinib hydrochloride was 89.2%. After treatment, the scores of daily life, emotional control, activity, social/family life and other scores of patients were higher than before treatment, and the total score (181.39±14.73) after treatment was higher than before treatment (160.73±12.16). The differences were statistically significant (P<0.05). Anlotinib hydrochloride had the highest incidence of hypertension in patients with non-small cell lung cancer after treatment, accounting for 13.5%, followed by hand-foot syndrome and thyroid dysfunction, accounting for 10.8% and 8.1%, respectively. Six of the patients had serious adverse reactions, accounting for 8.1%. Conclusion: Anlotinib has certain advantages in the efficacy and safety of treatment of non-small cell lung cancer, and can improve the quality of life of patients, and it can provide treatment for patients with second-and third-line chemotherapy failure and the refractory.

Key words： Non-small cell lung cancer(NSCLC) Anlotinib Hydrochloride Quality of life

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Yu
	LI Yanfang
	ZHANG Gaiqin
	et al

Cite this article:

ZHANG Yu,LI Yanfang,ZHANG Gaiqin, et al. The Clinical Efficacy of Anlotinib Hydrochloride in the Treatment of Advanced Non-Small Cell Lung Cancer Patients[J]. HeBei Med, 2020, 26(10): 1742-1746.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2020.10.037 OR http://www.hbyxzzs.cn/EN/Y2020/V26/I10/1742

[1] 郭浩,周淑妮,冉瑞智.吉非替尼联合培美曲塞和顺铂治疗晚期非小细胞肺癌的安全性和有效性[J].现代肿瘤医学,2019,27(5):796~800.
[2] 刘威,周灵,沈红梅.晚期非小细胞肺癌患者化疗前后睡眠及生活质量变化及相互关系的研究[J].华中科技大学学报(医学版),2019,48(1):98~103.
[3] 陈吓妹,谢晶晶,方莉莉.吉非替尼治疗晚期非小细胞肺癌的临床效果观察[J].临床合理用药杂志,2018,11(29):45~46.
[4] 闫森,郭克锋,肖青兰,等.培美曲塞联合顺铂治疗晚期非小细胞肺癌的临床效果[J].河南医学研究,2020,29(5):847~848.
[5] 张慧芳,马金沙,李璐,等.EGFR-TKIs一线治疗晚期非小细胞肺癌的有效性和安全性比较:网状Meta分析[J].中华疾病控制杂志,2020,24(2):210~216.
[6] He Y. Molecular targeted therapeutic drugs for lung cancer[J]. Journal of Practical Rural Doctors, 2017, 24(4): 14~16.
[7] 朱双媚,孙晓南.阿帕替尼对二、三线药物化疗失败晚期肺癌的效果观察[J].浙江医学,2019,41(2):167~169.
[8] Ettinger DS, Wood DE, Akerley W, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology[J]. Natl Compr Canc Netw, 2017, 15(4): 504~535.
[9] 秦萌萌,马德宾,李昕玲,等.鼠李素(Rhamnetin)对新型分子靶向药物安罗替尼(Anlotinib)杀伤非小细胞肺癌细胞的增敏作用[J].科学技术与工程,2018,18(24):213~219.
[10] 斯晓燕,王汉萍,张晓彤,等.安罗替尼治疗晚期非小细胞肺癌16例临床分析[J].中华内科杂志,2018,57(11):830~834.
[11] 辛涛,金发光,刘伟,等.盐酸安罗替尼胶囊治疗晚期非小细胞肺癌的临床研究[J].中华肺部疾病杂志(电子版),2018,11(5):559~562.
[12] Si X, Zhang L, Wang H, et al. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase Ⅲ trial of anlotinib in patients with advanced non-small cell lung cancer[J]. Lung Cancer, 2018, 122: 32~37.
[13] 刘佳勇,樊征夫,李舒,等.盐酸安罗替尼胶囊治疗晚期软组织肉瘤Ⅱb期多中心临床试验的单中心数据分析[J].中国肿瘤临床,2018,45(20):1066~1070.